Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA).

What if Teresa of Ávila (1515–1582)—whose body is on public display for the first time in 110 years—influenced René Descartes ...

Cogito, ergo sum, as the phrase goes in Latin, cemented the way the Western world would continue to define the self for the ...

Valued at a market cap of $13.4 billion, Descartes Systems (TSX:DSG) is a tech stock that has returned more than 700% to ...

Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash. Cartesian Therapeutics, Inc. has announced the ...

Descartes Underwriting has strengthened its leadership team with the appointments of Sophie Bassoulet as Head of Operations ...

Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, ...